Assay

Emosis and Accellix Announce Intent to Form a Joint Venture, EmoCellix

Retrieved on: 
Thursday, December 6, 2018
Assay, Biochemistry, Titration, Joint venture, JV

The French company Emosis and Accellix today announced that they have signed a letter of intent to form a joint venture (JV) to be equally owned by the two companies.

Key Points: 
  • The French company Emosis and Accellix today announced that they have signed a letter of intent to form a joint venture (JV) to be equally owned by the two companies.
  • EmoCellix will be dedicated to deliver a complete solution integrating Emosis novel hemostasis cytomolecular diagnostic tests with Accellix innovative assay delivery platform.
  • Accellix would grant the JV with the rights to use Accellix as a delivery platform for its assays and would provide support for adapting the assays to the platform.
  • The JV will be owned 50% by Accellix and 50% by Emosis, and customers will remain free to purchase non-integrated products and services from Accellix and Emosis.

Congruence Study Between Two ctDNA Liquid Biopsy Testing in mBC Patients and Prognostic Value in Combination with CTCs, Investigators to Report at SABCS 2018

Retrieved on: 
Monday, December 3, 2018
Medicine, DNA, Anatomical pathology, Oncology, Circulating tumor DNA, Neoplasms, Assay, Metastatic breast cancer

In this week's SABCS annual conference, clinicians and scientists from Northwestern University present an independent study that shows consistent results between Guardant Health and Predicine ctDNA assay platforms.

Key Points: 
  • In this week's SABCS annual conference, clinicians and scientists from Northwestern University present an independent study that shows consistent results between Guardant Health and Predicine ctDNA assay platforms.
  • Specifically, both PredicinePLUS and Guardant360 ctDNA assays identified similar type of genomic alternations in metastatic breast cancer (mBC) patients.
  • Of note, the ctDNA results from the 180-gene PredicinePLUS assay additionally demonstrate a significant correlation with treatment response and overall survival.
  • Complete results from the study will be presented at SABCS on November 7, 2018 in accordance with the SABCS embargo policy.

Natera Receives Unique Z-Code for Its Kidney Transplant Rejection Monitoring Test

Retrieved on: 
Wednesday, November 28, 2018
Chemistry, Laboratory techniques, Biology, Nature, Biotechnology, Natera, Clinical Laboratory Improvement Amendments, Medical laboratory, Assay, Organ transplantation, Polymerase chain reaction, Transplant rejection

Natera recently completed analytical and clinical validation of its donor-derived cell-free DNA assay, leveraging its proprietary massively-multiplexed PCR technology.

Key Points: 
  • Natera recently completed analytical and clinical validation of its donor-derived cell-free DNA assay, leveraging its proprietary massively-multiplexed PCR technology.
  • "There is a significant unmet need for more accurate, non-invasive tools to monitor transplant rejection," said Dr. Paul Billings, Natera's Chief Medical Officer and Senior Vice President, Medical Affairs.
  • "Natera's assay may help physicians detect rejection events earlier, avoid unnecessary biopsies, and more safely optimize immunosuppression levels."
  • Natera operates an ISO 13485-certified and CAP-accredited laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, Calif.

The global lateral flow assay market projected to grow at a CAGR of 7.7%

Retrieved on: 
Wednesday, November 28, 2018
Chemistry, Laboratory techniques, Nature, Immunologic tests, Assay, Biochemistry, Titration, Lateral flow test, Reagent

The global lateral flow assay market is projected to reach USD 8.7 billion by 2023 from USD 6.0 billion in 2018 growing at a CAGR of 7.7% from 2018 to 2023.

Key Points: 
  • The global lateral flow assay market is projected to reach USD 8.7 billion by 2023 from USD 6.0 billion in 2018 growing at a CAGR of 7.7% from 2018 to 2023.
  • On the basis of product, the lateral flow assay market is segmented into kits & reagents and lateral flow readers.The lateral flow readers segment is expected to register the highest CAGR during the forecast period.
  • North America held the largest share of the global lateral flow assay market in 2017.
  • The report analyzes the global lateral flow assay market by product, application, technique, end user, and region
    Market Development: Comprehensive information on the lucrative emerging regions by product, application, technique, end user, and region
    Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global lateral flow assay market
    Competitive Assessment: In-depth assessment of market shares, growth strategies, and products of leading players in the global lateral flow assay market

SQI Diagnostics to Announce Fourth Quarter and Fiscal 2018 Results

Retrieved on: 
Tuesday, November 27, 2018
Laboratory techniques, Assay, Biochemistry, Titration, Medical tests, Nature, Biology, Laboratory equipment, Molecular diagnostics, Science

SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets.

Key Points: 
  • SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets.
  • SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one.
  • This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality.
  • This press release contains certain words and statements, which may constitute "forward-looking statements" within the meaning of applicable securities laws.

Roche launches first IVD pan-TRK immunohistochemistry assay

Retrieved on: 
Tuesday, November 27, 2018
Laboratory techniques, Chemistry, Tyrosine kinase receptors, Biology, Medicine, Histology, Immunohistochemistry, Pathology, Staining, Trk receptor, Assay, TRK

TUCSON, Ariz., Nov. 27, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch of the VENTANA pan-TRK (EPR17341) Assay, the first automated in vitro diagnostic (IVD) immunohistochemistry (IHC) assay to detect tropomyosin receptor kinase (TRK) proteins in cancer.

Key Points: 
  • TUCSON, Ariz., Nov. 27, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch of the VENTANA pan-TRK (EPR17341) Assay, the first automated in vitro diagnostic (IVD) immunohistochemistry (IHC) assay to detect tropomyosin receptor kinase (TRK) proteins in cancer.
  • This assay can be used to perform analytic studies, including prevalence in solid tumors.
  • The VENTANA pan-TRK (EPR17341) Assay is available for use on Roche's BenchMark series of IHC/ISH automated staining instruments.
  • Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

Roche launches first IVD pan-TRK immunohistochemistry assay

Retrieved on: 
Tuesday, November 27, 2018
Laboratory techniques, Chemistry, Tyrosine kinase receptors, Biology, Medicine, Histology, Immunohistochemistry, Pathology, Staining, Trk receptor, Assay, TRK

TUCSON, Arizona, Nov. 27, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch of the VENTANA pan-TRK (EPR17341) Assay, the first automated in vitro diagnostic (IVD) immunohistochemistry (IHC) assay to detect tropomyosin receptor kinase (TRK) proteins in cancer.

Key Points: 
  • TUCSON, Arizona, Nov. 27, 2018 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the global launch of the VENTANA pan-TRK (EPR17341) Assay, the first automated in vitro diagnostic (IVD) immunohistochemistry (IHC) assay to detect tropomyosin receptor kinase (TRK) proteins in cancer.
  • This assay can be used to perform analytic studies, including prevalence in solid tumors.
  • The VENTANA pan-TRK (EPR17341) Assay is available for use on Roche's BenchMark series of IHC/ISH automated staining instruments.
  • Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

The apoptosis assays market is expected to reach USD 5.9 billion by 2023 from an estimated USD 3.6 billion in 2018, at a CAGR of 10.5%

Retrieved on: 
Monday, November 26, 2018
Biology, Laboratory techniques, Medicine, Chemistry, Blood tests, Cell biology, Clinical pathology, Medical tests, Assay, Flow cytometry, Cytometry, Apoptosis

The apoptosis assays market is expected to reach USD 5.9 billion by 2023 from an estimated USD 3.6 billion in 2018, at a CAGR of 10.5%.

Key Points: 
  • The apoptosis assays market is expected to reach USD 5.9 billion by 2023 from an estimated USD 3.6 billion in 2018, at a CAGR of 10.5%.
  • However, high investments required for research and development is expected to restrain the growth of this market to a certain extent during the forecast period.
  • On the basis of detection technology, the apoptosis assays market is segmented into flow cytometry, cell imaging & microscopy, spectrophotometry, and other detection technologies.The cell imaging & microscopy segment is expected to register the highest CAGR during the forecast period.
  • Firms purchasing the report could use one or any combination of the below-mentioned five strategies for strengthening the market.

The apoptosis assays market is expected to reach USD 5.9 billion by 2023 from an estimated USD 3.6 billion in 2018, at a CAGR of 10.5%

Retrieved on: 
Monday, November 26, 2018
Biology, Laboratory techniques, Medicine, Chemistry, Blood tests, Cell biology, Clinical pathology, Medical tests, Assay, Flow cytometry, Apoptosis, Cytometry

The apoptosis assays market is expected to reach USD 5.9 billion by 2023 from an estimated USD 3.6 billion in 2018, at a CAGR of 10.5%.

Key Points: 
  • The apoptosis assays market is expected to reach USD 5.9 billion by 2023 from an estimated USD 3.6 billion in 2018, at a CAGR of 10.5%.
  • However, high investments required for research and development is expected to restrain the growth of this market to a certain extent during the forecast period.
  • On the basis of detection technology, the apoptosis assays market is segmented into flow cytometry, cell imaging & microscopy, spectrophotometry, and other detection technologies.The cell imaging & microscopy segment is expected to register the highest CAGR during the forecast period.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Cell Based Assays Market is Estimated to be Worth US$19,710.7 Mn by 2022, Says TMR

Retrieved on: 
Monday, November 26, 2018
Assay, Biochemistry, Titration, Transparency Market Research, Biotechnology, Nature

The global market for cell based assays stood at US$13,576.7 million in 2017.

Key Points: 
  • The global market for cell based assays stood at US$13,576.7 million in 2017.
  • The global cell based assays market is driven increasingly by the rising demand for cell-based methodologies among pharmaceutical and biotechnology companies for drug discovery screening, world over.
  • The segment is anticipated to retain its lead in the cell based assays market in next few years.
  • The presence of a large number of players makes the global cell based assays market increasingly fragmented, finds Transparency Market Research (TMR).